ANCA-associated vasculitis: New therapeutic concepts and strategies;ANCA-assoziierte vaskulitiden: Neue konzepte und strategien in der therapie

Internist

Volumn 41, Issue 10, 2000, Pages 1112-1119

  De Groot, K ^a   Haubitz, M ^a   Haller, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; CD18 ANTIGEN; CD40 ANTIGEN; CYTOKINE; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; TERIFLUNOMIDE;

CHURG STRAUSS SYNDROME; DIAGNOSTIC PROCEDURE; DRUG EFFECT; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; REVIEW; SEROLOGY; STEM CELL TRANSPLANTATION; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHURG-STRAUSS SYNDROME; CYTOKINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0033794394     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050670     Document Type: Review

References (38)

1. Systemic vasculitis in the 1980s - Is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?
2. Primar systemische vaskulitiden. Teil III pathogenese und therapie
3. Wegener's granulomatosis: An analysis of 158 patients
4. An interdisciplinary approach to the care of patients with Wegener's granulomatosis. Long term outcome in 155 patients
5. Mycophenolate mofetil (RS61443): Nothing new under the sun or an important break-through in the field of transplantation?
6. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
7. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement
8. Mycophenolate mofetil for the treatment of Takayasu Arteritis: Report of three cases
9. Tolerance of MMF in endstage renal disease patients with ANCA-associated vasculitis
10. Short analytical review. Mechanism of action of leflunomide in rheumatoid arthritis
11. Mechanism of action of leflunomide in rheumatoid vasculitis
12. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double blind, randomized, multicenter trial. European Leflunomide Study Group
13. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
14. Maintenance of remission with leflunomide in Wegener's granulomatosis
15. Efficacy, safety and pharmacokinetics of the combination of methotrexate and leflunomide in patients with active rheumatoid arthritis
16. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group
17. Deoxyspergualin: Mechanism of action and pharmacokinetics
18. New immunomodulating concepts in ANCA-associated disease
19. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis
20. Cytokine profiles in Wegener's granulomatosis. Predominance of type 1 (TH1) in the granulomatous inflammation
21. Review article: The efficacy of infliximab in Crohn's disease - Healing of fistulae
22. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
23. Infliximab (chimeric anti tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
24. Review article: Safety of infliximab in clinical trials
25. Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis
26. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
27. Etanercept in Wegener' granulomatosis (WG): Design of a randomized multi-center trial
28. Integrins and other cell adhesion molecules
29. Intervention in experimental anti-MPO-associated cresentic glomerular nephritis by monoclonal antibodies against adhesion molecules
30. Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation
31. Long-term survival of skin allograft induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4+ T cells, interferon γ and CTLA4
32. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis
33. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides
34. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production
35. Hematopoietic stem cell transplantation in rheumatic diseases
36. Pros and cons of stem cell transplantation for autoimmune disease
37. Autologous stem cell transplantation for autoimmune diseases. Issues in protocol development
38. The pathogenesis of angiitis